Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Developments in the Cancer Immunotherapy Market

PR Newswire October 20, 2017

Biotech Stock Performance Review -- Agenus, Akebia Therapeutics, Acorda Therapeutics, and Advaxis

PR Newswire October 20, 2017

Advaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare Conference

Business Wire September 21, 2017

Two Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting

Business Wire September 19, 2017

Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference

Business Wire September 18, 2017

10 Biggest Mid-Day Losers For Thursday

Benzinga.com  September 12, 2017

Mid-Day Market Update: Advaxis Drops Following Q3 Results; Aethlon Medical Shares Climb

Benzinga.com  September 12, 2017

Advaxis Reports Business Update and Third Quarter 2017 Results

Business Wire September 11, 2017

Stocks Under Scanner in the Biotech Space -- Acorda Therapeutics, Advaxis, Xbiotech, and Akebia Therapeutics

PR Newswire September 11, 2017

Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Business Wire August 2, 2017

Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders

Business Wire July 13, 2017

15 Biggest Mid-Day Losers For Friday

Benzinga.com  July 7, 2017

Stocks To Watch For July 7, 2017

Benzinga.com  July 7, 2017

Advaxis Announces Change in Leadership

Business Wire July 6, 2017

Advaxis’ Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017

Business Wire June 26, 2017

Advaxis to Present at 2017 BIO International Convention

Business Wire June 16, 2017

Advaxis to Be Featured on Worldwide Business with kathy ireland®

Business Wire June 14, 2017

Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day

Business Wire June 13, 2017

Advaxis to Webcast Investor & Analyst Day 2017

Business Wire June 9, 2017

Update: Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available

Business Wire June 8, 2017